All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
On April 28, 2021, the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application to evaluate NKX019 for relapsed or refractory (R/R) B-cell malignancies.
This decision permits the start of a phase I clinical trial investigating NKX019 for the treatment of patients with R/R B-cell malignancies, such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
NKX019 is an allogeneic, CD19-directed chimeric antigen receptor (CAR)-natural killer (NK) cell therapy developed from the peripheral blood of healthy donors. The product undergoes genetic editing to express membrane-bound IL-15, a cytokine central to the survival, proliferation, persistence, and activity of NK cells.
NKX019 offers an off-the-shelf approach to cancer immunotherapy, and the phase I clinical trial is due to commence in the second half of 2021.
Nkarta Therapeutics. Nkarta receives NKX019 IND clearance from U.S. Food and Drug Administration for treatment of relapsed/refractory B cell malignancies. https://ir.nkartatx.com/news-releases/news-release-details/nkarta-receives-nkx019-ind-clearance-us-food-and-drug. Published Apr 28, 2021. Accessed May 04, 2021.
SOHO 2019 | What are the novel prognostic factors for the treatment of patients with CLL?
At SOHO 2019, we spoke to Dr Alessandra Ferrajoli about novel prognostic factors and how they are used for the treatment of patients with chronic lymphocytic...
Prevalence of BTK and PLCG2 mutations in a CLL cohort still on ibrutinib after three years
Anne Quinquenel conducted a study to investigate patients from the FILO study, who were still on ibrutinib after three years.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox